Alterity Therapeutics Limited
OTC: PRNAF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- David A. Stamler
- Employees
- 9
- Headquarters
- Melbourne, Australia
- IPO year
- 2012
- Market cap
- $12.0M
- Website
- http://www.alteritytherapeutics.com
Loading PRNAF…
Loading profile data…Frequently asked questions about PRNAF
What does Alterity Therapeutics Limited (PRNAF) do?
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It...
Where does PRNAF trade?
Alterity Therapeutics Limited (PRNAF) trades on the Other OTC.
What sector is PRNAF in?
Alterity Therapeutics Limited (PRNAF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Alterity Therapeutics Limited?
David A. Stamler is the chief executive officer of Alterity Therapeutics Limited (PRNAF).
Where is Alterity Therapeutics Limited headquartered?
Alterity Therapeutics Limited is headquartered in Australia.
Does PRNAF pay a dividend?
Alterity Therapeutics Limited (PRNAF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PRNAF go public?
Alterity Therapeutics Limited (PRNAF) completed its initial public offering in 2012.